RenovoRx enters severance deal with VP/Controller Kocak; annual meeting re-elects six directors

RenovoRx, Inc.

Severance provides 50% of base salary on qualifying termination; 100% plus full equity vesting if within 12 months of a change in control.
Kocak also receives 6 months COBRA (12 months in change in control) and pro-rata bonus.
At June 6 annual meeting, all six nominees re-elected: Bagai, Agah, Macfarlane, Marton, Ryan, Spiegel.
Agreement mirrors terms for other RenovoRx executive officers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.